Evidence map›Paper›PMID 24599320›Full record

ArticlePloS one2014

Impact of donor and recipient single nucleotide polymorphisms of IL28B rs8099917 in living donor liver transplantation for hepatitis C.

Nobuhiro Harada, Sumihito Tamura, Yasuhiko Sugawara, Junichi Togashi, Takeaki Ishizawa, Junichi Kaneko, Taku Aoki, Yoshihiro Sakamoto, Kiyoshi Hasegawa, Tomohiro Tanaka and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Nobuhiro HaradaDivision of Artificial Organ and Transplantation, The University of Tokyo Hospital, Tokyo, Japan.
Sumihito TamuraDivision of Artificial Organ and Transplantation, The University of Tokyo Hospital, Tokyo, Japan.
Yasuhiko SugawaraDivision of Artificial Organ and Transplantation, The University of Tokyo Hospital, Tokyo, Japan; Organ Transplantation Service, The University of Tokyo Hospital, Tokyo, Japan.
Junichi TogashiDivision of Artificial Organ and Transplantation, The University of Tokyo Hospital, Tokyo, Japan.
Takeaki IshizawaDivision of Hepato-Biliary and Pancreatic Surgery, Department of Surgery, The University of Tokyo Hospital, Tokyo, Japan.
Junichi KanekoDivision of Artificial Organ and Transplantation, The University of Tokyo Hospital, Tokyo, Japan.
Taku AokiDivision of Hepato-Biliary and Pancreatic Surgery, Department of Surgery, The University of Tokyo Hospital, Tokyo, Japan.
Yoshihiro SakamotoDivision of Hepato-Biliary and Pancreatic Surgery, Department of Surgery, The University of Tokyo Hospital, Tokyo, Japan.
Kiyoshi HasegawaDivision of Hepato-Biliary and Pancreatic Surgery, Department of Surgery, The University of Tokyo Hospital, Tokyo, Japan.
Tomohiro TanakaOrgan Transplantation Service, The University of Tokyo Hospital, Tokyo, Japan.
Noriyo YamashikiOrgan Transplantation Service, The University of Tokyo Hospital, Tokyo, Japan.
Norihiro KokudoDivision of Hepato-Biliary and Pancreatic Surgery, Department of Surgery, The University of Tokyo Hospital, Tokyo, Japan; Organ Transplantation Service, The University of Tokyo Hospital, Tokyo, Japan.
University of Tokyo Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Single nucleotide polymorphisms of interleukin-28B (IL28B) rs8099917 are reported to be associated with virologic clearance in interferon-and ribavirin -based treatment for hepatitis C virus (HCV)-infected patients. We examined virologic response in accordance with IL28B polymorphisms in our living donor liver transplantation series under a preemptive interferon and RBV treatment approach. Adequate DNA samples from both the recipient and donor for the study of single nucleotide polymorphisms of IL28B were available from 96 cases and were the subjects of the present study. Various clinical factors related with virologic response including early virologic response (EVR) and sustained virologic response (SVR) were examined. Totally 51% presented with EVR and 44% achieved SVR. Presence of the major allele (TT) in either the recipient or the donor corresponded to SVR of 53% and 48%. Presence of the minor allele (TG or GG) corresponded to SVR of 26% and 32%. Multivariate analysis revealed that genotype of HCV or EVR, but not IL28B polymorphisms in either the recipient or donor, was an independent factor for achieving SVR. When virologic response to treatment was incorporated into analysis, the impact of IL28B polymorphism on virological clearance remained relative to other factors and was not significantly independent.

Indexed as

Living DonorsPolymorphism, Single NucleotideAdolescentAdultAgedAntiviral AgentsDrug Therapy, CombinationGenetic Association StudiesGenotypeHepacivirusHepatitis C, ChronicHumansInterferon-alphaInterferon alpha-2Interferon LambdaInterferonsAntiviral AgentsInterferon-alphaInterferon alpha-2Interferon Lambdainterferon-lambda, humanInterferonsInterleukinsRecombinant ProteinsRibavirin

Identifiers

PMID24599320
PMCPMC3944011
OpenAlexW2334670730

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.